Expression of HER2/erbB-2 correlates with survival in osteosarcoma Journal Article


Authors: Gorlick, R.; Huvos, A. G.; Heller, G.; Aledo, A.; Beardsley, G. P.; Healey, J. H.; Meyers, P. A.
Article Title: Expression of HER2/erbB-2 correlates with survival in osteosarcoma
Abstract: Purpose: In osteosarcoma, prognostic factors at diagnosis other than clinical stage have not been clearly identified. The aim of this study was to determine whether human epidermal growth factor receptor 2 (HER2)/erbB-2, p- glycoprotein, or p53 expression correlated with histologic response to preoperative chemotherapy or event-free survival. Patients and Methods: We performed a retrospective immunohistochemical study on material obtained from patients treated on the Memorial Sloan-Kettering Cancer Center T12 protocol between 1986 and 1993. Paraffin-embedded tissue was identified from 53 patients (73% of patients enrolled onto protocol) and stained for HER2/erbB- 2, p53, and p-glycoprotein expression using standard monoclonal antibodies and methods. Results: At the time of initial biopsy, 20 (42.6%) of 47 samples demonstrated high levels of HER2/erbB-2 expression. Higher frequencies of expression were observed in samples from patients with metastatic disease at presentation and at the time of relapse. Expression of HER2/erbB-2 correlated with a significantly worse histologic response (P = .03). In patients presenting with nonmetastatic disease, expression of HER2/erbB-2 at the time of initial biopsy was associated with a significantly decreased event-free survival (47% v 79% at 5 years, P = .05). p53 and p-glycoprotein expression did not correlate with histologic response or patient event-free survival. Conclusion: The correlation of HER2/erbB-2 expression with histologic response to preoperative chemotherapy and event-free survival in this study suggests that HER2/erbB-2 should be evaluated prospectively as a prognostic indicator. The correlation also suggests that clinical trials of antibodies that target this receptor, such as recombinant humanized anti-HER2 monoclonal antibody (Herceptin; Genentech, San Francisco, CA), should be considered for the treatment of osteosarcoma.
Keywords: osteosarcoma; adolescent; adult; cancer survival; child; controlled study; human tissue; protein expression; school child; treatment outcome; bone neoplasms; child, preschool; cancer surgery; retrospective studies; unclassified drug; major clinical study; histopathology; cancer recurrence; cancer adjuvant therapy; preoperative evaluation; disease association; metastasis; epidermal growth factor receptor; neoplasm proteins; protein p53; monoclonal antibody; tumor suppressor protein p53; receptor, erbb-2; trastuzumab; protein determination; p-glycoprotein; glycoprotein p; humans; prognosis; human; male; female; priority journal; article
Journal Title: Journal of Clinical Oncology
Volume: 17
Issue: 9
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 1999-09-01
Start Page: 2781
End Page: 2788
Language: English
PUBMED: 10561353
PROVIDER: scopus
DOI/URL:
Notes: Article -- Export Date: 16 August 2016 -- Source: Scopus